SCHEDULE 13G/A: Perceptive Advisors and Joseph Edelman Disclose 6.8% Stake in Rhythm Pharmaceuticals
Beneficial Ownership Report
Perceptive Advisors LLC and Joseph Edelman, along with affiliated funds, have disclosed a combined beneficial ownership of 6.8% in Rhythm Pharmaceuticals, Inc., totaling 4,423,441 shares.
Summary
- Perceptive Advisors LLC and Joseph Edelman, along with their affiliated entities Perceptive Life Sciences Master Fund, Ltd. and Perceptive Discovery ID LP, collectively beneficially own 4,423,441 shares of Rhythm Pharmaceuticals, Inc. common stock.
- This aggregate ownership represents 6.8% of the Issuer's outstanding common stock.
- The ownership percentage is based on 63,621,472 shares of common stock outstanding as of April 30, 2025, as reported in Rhythm Pharmaceuticals' Form 10-Q filed on May 7, 2025.
- The reported shares include common stock directly held and shares convertible from Series A Convertible Preferred Stock at a rate of 20.8333 shares of common stock per $1,000 liquidation preference.
- Specifically, Perceptive Life Sciences Master Fund, Ltd. holds 2,548,445 direct common shares and Series A Convertible Preferred Stock convertible into 416,666 common shares, totaling 2,965,121 shares (4.5%).
- Perceptive Discovery ID LP holds Series A Convertible Preferred Stock convertible into 1,458,330 common shares (2.2%).
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership, which is inherently neutral. However, the disclosure of a significant stake (6.8%) by a prominent life sciences investment firm like Perceptive Advisors could be interpreted as a positive signal of institutional confidence in Rhythm Pharmaceuticals, Inc.
Positives
- A significant investment firm, Perceptive Advisors, and its affiliates have disclosed a substantial 6.8% beneficial ownership in Rhythm Pharmaceuticals, potentially signaling confidence in the company's future.
Future Outlook
NA
Industry Context
This filing reflects a significant passive investment by a specialized life sciences fund in a pharmaceutical company. Such investments are common in the biotechnology and pharmaceutical sectors, where institutional investors often take substantial positions in companies with promising pipelines or market positions. The disclosure of a 6.8% stake by Perceptive Advisors, a prominent healthcare-focused investment firm, indicates their continued interest in the sector and potentially in Rhythm Pharmaceuticals' specific therapeutic areas.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor sentiment and potentially the stock price, signaling confidence from a major investment firm.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement |
| 04/30/2025 | Date as of which 63,621,472 shares of Common Stock were outstanding, as reported in Issuer's Quarterly Report on Form 10-Q |
| 05/07/2025 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC |
| 05/15/2025 | Date of signing of the Schedule 13G filing |
Keywords
Rhythm Pharmaceuticals, Perceptive Advisors, Joseph Edelman, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology, Pharmaceuticals, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.